

Precision Medicine Market by Type (Inhibitors, Monoclonal Antibodies, Cell & Gene Therapy, Antivirals, Antiretroviral), Indication (Oncology, Rare diseases, Hematology, Infectious), End user (Hospitals & Clinics, Home care) & Region - Global Forecast to 2028

Market Report | 2023-09-06 | 234 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The precision medicine market is expected to reach USD 50.2 billion by 2028 from USD 29.1 billion in 2023, at a CAGR of 11.5% during the forecast period. The key factors driving the growth of the precision medicine market include growing initiatives related to genomic research, and increasing number of regulatory approvals for personalized therapeutics. Moreover, rising demand for cell and gene therapies is an opportunity area for this market.

The precision medicine market has been segmented based on type, indication, end user and region.

"By type, the monoclonal antibodies segment accounted for the second largest share of the precision medicine market"

Based on type, the precision medicine market is categorized into inhibitor drugs, monoclonal, cell & gene therapy, antiviral & antiretroviral drugs, and other therapeutic products. In 2022, monoclonal antibodies accounted for the highest growth rate owing to factors such as benefits offered by monoclonal antibodies over traditional medicines. These advantages have led to shifting focus of the clinical pipeline dominantly on monoclonal antibodies.

"By end user, the hospitals and clinics segment accounted for the largest share in the precision medicine market"

Based on end user, the precision medicine market is segmented into hospitals and clinics and home care settings. In 2022, the hospitals and clinics segment accounted for a largest share of the precision medicine market. Growth in this market segment can be attributed to availability of services such as genetic testing, diagnostics and counselling in hospital setups. Besides, hospitals have easy accessibility of therapeutic products which are made available for patients opting for precision medicine regime.

?

"North America: the largest share of the precision medicine market"

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

North America accounted for the largest share of the precision medicine market. The large share of the North America region can be attributed to major factors such as presence of technologically advanced infrastructure in healthcare settings offering precision medicines, and easy accessibility to advanced therapeutics among others. Besides, the region has a well established healthcare system which further supports the growth of this market.

"Europe: The fastest-growing region in the precision medicine market."

The Europe precision medicine market is projected to grow at the highest CAGR during the forecast period. This is attributed to one of the major factors including the growing initiatives for precision medicine advancements with presence of some of the key players in the market. Some examples of these players include F. Hoffmann-La Roche Ltd. (Switzerland), Novartis AG (Switzerland), AstraZeneca (UK), GlaxoSmithKline plc (UK) among others.

The primary interviews conducted for this report can be categorized as follows:

-□By Respondent: Supply Side- 70% and Demand Side 30%

-□By Designation: Managers - 45%, Directors- 30%, and Executives - 25%

-□By Country: North America- 25%, Europe- 25%, Asia Pacific- 40%, Latin America- 5%, and Middle East- 2.5% & Africa- 2.5%

Prominent Players

-□F. Hoffmann-La Roche Ltd. (Switzerland)

-□Novartis AG (Switzerland)

-□Pfizer Inc. (US)

-□Bristol Myers Squibb (US)

-□AstraZeneca (UK)

-□Gilead Sciences, Inc. (US)

-□AbbVie Inc. (US)

-□Eli Lilly and Company (US)

-□GlaxoSmithKline plc (UK)

-□Sanofi (France)

-□Johnson & Johnson (US)

-□Merck KGaA (Germany)

-□Amgen, Inc. (US)

-□Takeda Pharmaceutical Company Limited (Japan)

-□Regeneron Pharmaceuticals, Inc. (US)

-□Sarepta Therapeutics, Inc. (US)

-□bluebird bio, Inc. (US)

-□Immunocore Holdings Plc (UK)

-□Blueprint Medicines Corporation (US)

-□Vertex Pharmaceuticals Incorporated (US)

-□Horizon Therapeutics Plc (Ireland)

-□Alnylam Pharmaceuticals, Inc. (US)

-□Rigel Pharmaceuticals, Inc. (US)

-□Taiho Pharmaceutical Co., Ltd. (Japan)

-□Seagen Inc. (US)

Research Coverage:

This report provides a detailed picture of the precision medicine market. It aims at estimating the size and future growth potential of the market across different segments, such as the type, indication, end user and region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the precision medicine market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.

The report provide insights on the following pointers"

- Analysis of key drivers (growth in genomic research, genetic testing and companion diagnostics), opportunities (cell and gene therapy demand), restraint (budget constraints) and challenges (challenges associated with precision medicines adoption) influencing the growth of the precision medicine market.
- Product Development/ Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the precision medicine market.
- Market Development: Comprehensive information about lucrative markets- the report analyses the precision medicine market across varied regions.
- Market Diversification: Exhaustive information about new products and service, untapped geographies, recent developments, and investments in the precision medicine market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players like F. Hoffmann-La Roche Ltd. (Switzerland), Novartis AG (Switzerland), Bristol Myers Squibb (US), Gilead Sciences, Inc. (US), AstraZeneca (UK), Pfizer Inc. (US), AbbVie Inc. (US), Eli Lilly and Company (US), , GlaxoSmithKline plc (UK), Sanofi (France), Johnson & Johnson (US), Merck KGaA (Germany), Amgen, Inc. (US), Takeda Pharmaceutical Company Limited (Japan) among others in the precision medicine market.

Table of Contents:

1□INTRODUCTION□	28
1.1□STUDY OBJECTIVES□	28
1.2□MARKET DEFINITION□	28
1.2.1□INCLUSIONS AND EXCLUSIONS□	29
1.3□MARKET SCOPE□	30
1.3.1□MARKETS COVERED□	30
FIGURE 1□PRECISION MEDICINE MARKET SEGMENTATION□	30
1.3.2□YEARS CONSIDERED□	30
1.4□CURRENCY CONSIDERED□	31
1.5□LIMITATIONS□	31
1.6□STAKEHOLDERS□	31
1.6.1□RECESSION IMPACT□	32
2□RESEARCH METHODOLOGY□	33
2.1□RESEARCH DATA□	33
FIGURE 2□RESEARCH DESIGN□	33
2.1.1□SECONDARY DATA□	34
2.1.2□PRIMARY DATA□	35
FIGURE 3□PRECISION MEDICINE MARKET: BREAKDOWN OF PRIMARIES□	35
2.2□MARKET SIZE ESTIMATION□	36
FIGURE 4□MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS□	36
FIGURE 5□MARKET SIZE ESTIMATION FOR PRECISION MEDICINE: REVENUE SHARE ANALYSIS□	37
2.2.1□INSIGHTS FROM PRIMARIES□	38
FIGURE 6□MARKET VALIDATION FROM PRIMARY EXPERTS□	38
2.2.2□SEGMENT ASSESSMENT (BY TYPE, INDICATION, AND END USER)□	38

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

FIGURE 7	MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH	38
2.3	GROWTH FORECAST	39
FIGURE 8	PRECISION MEDICINE MARKET: CAGR PROJECTIONS	40
FIGURE 9	PRECISION MEDICINE MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES	40
2.4	MARKET BREAKDOWN AND DATA TRIANGULATION	41
FIGURE 10	DATA TRIANGULATION METHODOLOGY	41
2.5	RESEARCH ASSUMPTIONS	42
2.6	RISK ANALYSIS	42
2.7	RECESSION IMPACT ANALYSIS	42
TABLE 1	GLOBAL INFLATION RATE PROJECTIONS, 2021-2027 (% GROWTH)	42
?		
3	EXECUTIVE SUMMARY	44
FIGURE 11	PRECISION MEDICINE MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)	44
FIGURE 12	PRECISION MEDICINE MARKET, BY INDICATION, 2023 VS. 2028	45
FIGURE 13	PRECISION MEDICINE MARKET, BY END USER, 2023 VS. 2028	45
FIGURE 14	GEOGRAPHICAL SNAPSHOT OF PRECISION MEDICINE MARKET	46
4	PREMIUM INSIGHTS	47
4.1	PRECISION MEDICINE MARKET OVERVIEW	47
FIGURE 15	INCREASING REGULATORY APPROVALS FOR PRECISION MEDICINES TO DRIVE MARKET	47
4.2	NORTH AMERICA: PRECISION MEDICINE MARKET, BY TYPE AND COUNTRY	48
FIGURE 16	INHIBITOR DRUGS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN NORTH AMERICA (2022)	48
4.3	PRECISION MEDICINE MARKET, BY INDICATION	48
FIGURE 17	ONCOLOGY SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD	48
4.4	PRECISION MEDICINE MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES	49
FIGURE 18	GERMANY TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD	49
5	MARKET OVERVIEW	50
5.1	INTRODUCTION	50
5.2	MARKET DYNAMICS	50
FIGURE 19	PRECISION MEDICINE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES	50
5.2.1	DRIVERS	51
5.2.1.1	Growing focus on genomic research	51
TABLE 2	INITIATIVES IN GENOMIC RESEARCH AND PRECISION MEDICINE	51
5.2.1.2	Growth in genetic testing and companion diagnostics	52
5.2.1.3	Increasing regulatory approvals for personalized therapeutics	52
5.2.2	RESTRAINTS	53
5.2.2.1	High costs of therapeutic development	53
5.2.3	OPPORTUNITIES	53
5.2.3.1	Rising demand for cell and gene therapies	53
5.2.4	CHALLENGES	53
5.2.4.1	Challenges associated with adoption of precision medicine	53
5.3	PORTER'S FIVE FORCES ANALYSIS	54
TABLE 3	PRECISION MEDICINE MARKET: PORTER'S FIVE FORCES ANALYSIS	54
5.3.1	THREAT OF NEW ENTRANTS	54
5.3.2	THREAT OF SUBSTITUTES	54
5.3.3	BARGAINING POWER OF SUPPLIERS	54
5.3.4	BARGAINING POWER OF BUYERS	54
5.3.5	INTENSITY OF COMPETITIVE RIVALRY	55

5.4	TECHNOLOGY ANALYSIS	55
?		
5.5	VALUE CHAIN ANALYSIS	55
FIGURE 20	PRECISION MEDICINE MARKET: VALUE CHAIN	55
5.5.1	RESEARCH & DEVELOPMENT	56
5.5.2	MANUFACTURING	56
5.5.3	DISTRIBUTION, MARKETING & SALES, AND POST-SALES ACTIVITIES	56
5.6	ECOSYSTEM ANALYSIS	56
FIGURE 21	PRECISION MEDICINE MARKET: ECOSYSTEM MAP	56
5.7	PATENT ANALYSIS	57
FIGURE 22	PATENT APPLICATIONS FOR PRECISION MEDICINE THERAPEUTIC PRODUCTS (JANUARY 2012-JULY 2023)	57
TABLE 4	PRECISION MEDICINE MARKET: INDICATIVE LIST OF PATENTS	57
5.8	PIPELINE ANALYSIS	58
TABLE 5	PRECISION MEDICINE THERAPEUTICS IN CLINICAL PIPELINE	58
5.9	SUPPLY CHAIN ANALYSIS	64
5.9.1	PROMINENT COMPANIES	64
5.9.2	SMALL AND MEDIUM-SIZED ENTERPRISES	64
5.9.3	END USERS	64
5.9.4	INVESTORS, VENTURE CAPITALISTS, AND FUNDING BODIES	64
5.9.5	REGULATORY BODIES	64
FIGURE 23	PRECISION MEDICINE THERAPEUTICS MARKET: SUPPLY CHAIN ANALYSIS	65
TABLE 6	PRECISION MEDICINE MARKET: SUPPLY CHAIN ECOSYSTEM	65
5.10	REGULATORY ANALYSIS	66
TABLE 7	NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	66
TABLE 8	EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	67
TABLE 9	ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	67
TABLE 10	REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	68
5.11	PRICING ANALYSIS	68
5.11.1	AVERAGE SELLING PRICE TREND OF KEY PLAYERS	68
TABLE 11	AVERAGE SELLING PRICE OF PRECISION MEDICINE THERAPEUTICS	68
5.12	TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES	69
5.13	KEY CONFERENCES AND EVENTS	69
TABLE 12	PRECISION MEDICINE MARKET: DETAILED LIST OF CONFERENCES & EVENTS (2023-2024)	69
5.14	KEY STAKEHOLDERS AND BUYING CRITERIA	70
5.14.1	KEY STAKEHOLDERS IN BUYING PROCESS	70
FIGURE 24	INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR PRECISION MEDICINE THERAPEUTICS IN HOSPITALS AND CLINICS	70
5.14.2	BUYING CRITERIA FOR PRECISION MEDICINE MARKET	71
FIGURE 25	KEY BUYING CRITERIA FOR HOSPITALS AND CLINICS	71
6	PRECISION MEDICINE MARKET, BY TYPE	72
6.1	INTRODUCTION	73
TABLE 13	PRECISION MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)	73
6.2	INHIBITOR DRUGS	73
6.2.1	ADVANTAGES OF HIGH ACCURACY AND AFFORDABILITY TO DRIVE MARKET	73
TABLE 14	APPROVED INHIBITOR DRUGS IN PRECISION MEDICINE MARKET (2022)	74
TABLE 15	PRECISION MEDICINE MARKET FOR INHIBITOR DRUGS, BY REGION, 2021-2028 (USD MILLION)	74
TABLE 16	NORTH AMERICA: PRECISION MEDICINE MARKET FOR INHIBITOR DRUGS, BY COUNTRY, 2021-2028 (USD MILLION)	75

TABLE 17	EUROPE: PRECISION MEDICINE MARKET FOR INHIBITOR DRUGS, BY COUNTRY, 2021-2028 (USD MILLION)	75
TABLE 18	ASIA PACIFIC: PRECISION MEDICINE MARKET FOR INHIBITOR DRUGS, BY COUNTRY, 2021-2028 (USD MILLION)	75
6.3	MONOCLONAL ANTIBODIES	76
6.3.1	HIGH SPECIFICITY AND GROWING CLINICAL PIPELINE OF MABS TO DRIVE MARKET	76
TABLE 19	PRECISION MEDICINE MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2021-2028 (USD MILLION)	76
TABLE 20	NORTH AMERICA: PRECISION MEDICINE MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)	77
TABLE 21	EUROPE: PRECISION MEDICINE MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)	77
TABLE 22	ASIA PACIFIC: PRECISION MEDICINE MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)	77
6.4	CELL AND GENE THERAPY	78
6.4.1	WIDE APPLICATIONS IN ONCOLOGY THERAPEUTICS TO FUEL MARKET	78
TABLE 23	PRECISION MEDICINE MARKET FOR CELL AND GENE THERAPY, BY REGION, 2021-2028 (USD MILLION)	78
TABLE 24	NORTH AMERICA: PRECISION MEDICINE MARKET FOR CELL AND GENE THERAPY, BY COUNTRY, 2021-2028 (USD MILLION)	79
TABLE 25	EUROPE: PRECISION MEDICINE MARKET FOR CELL AND GENE THERAPY, BY COUNTRY, 2021-2028 (USD MILLION)	79
TABLE 26	ASIA PACIFIC: PRECISION MEDICINE MARKET FOR CELL AND GENE THERAPY, BY COUNTRY, 2021-2028 (USD MILLION)	79
6.5	ANTIVIRAL AND ANTIRETROVIRAL DRUGS	80
6.5.1	MINIMAL SIDE EFFECTS DUE TO TARGETED APPROACH TO SUPPORT MARKET GROWTH	80
TABLE 27	PRECISION MEDICINE MARKET FOR ANTIVIRAL & ANTIRETROVIRAL DRUGS, BY REGION, 2021-2028 (USD MILLION)	80
TABLE 28	NORTH AMERICA: PRECISION MEDICINE MARKET FOR ANTIVIRAL & ANTIRETROVIRAL DRUGS, BY COUNTRY, 2021-2028 (USD MILLION)	81
TABLE 29	EUROPE: PRECISION MEDICINE MARKET FOR ANTIVIRAL & ANTIRETROVIRAL DRUGS, BY COUNTRY, 2021-2028 (USD MILLION)	81
TABLE 30	ASIA PACIFIC: PRECISION MEDICINE MARKET FOR ANTIVIRAL & ANTIRETROVIRAL DRUGS, BY COUNTRY, 2021-2028 (USD MILLION)	81
?		
6.6	OTHER THERAPEUTIC PRODUCTS	82
TABLE 31	PRECISION MEDICINE MARKET FOR OTHER THERAPEUTIC PRODUCTS, BY REGION, 2021-2028 (USD MILLION)	82
TABLE 32	NORTH AMERICA: PRECISION MEDICINE MARKET FOR OTHER THERAPEUTIC PRODUCTS, BY COUNTRY, 2021-2028 (USD MILLION)	82
TABLE 33	EUROPE: PRECISION MEDICINE MARKET FOR OTHER THERAPEUTIC PRODUCTS, BY COUNTRY, 2021-2028 (USD MILLION)	83
TABLE 34	ASIA PACIFIC: PRECISION MEDICINE MARKET FOR OTHER THERAPEUTIC PRODUCTS, BY COUNTRY, 2021-2028 (USD MILLION)	83
7	PRECISION MEDICINE MARKET, BY INDICATION	84
7.1	INTRODUCTION	85
TABLE 35	PRECISION MEDICINE MARKET, BY INDICATION, 2021-2028 (USD MILLION)	85
7.2	ONCOLOGY	85
7.2.1	INCREASING PRODUCT APPROVALS FOR CANCER THERAPEUTICS TO DRIVE MARKET	85
TABLE 36	PRECISION MEDICINE MARKET FOR ONCOLOGY, BY REGION, 2021-2028 (USD MILLION)	86
TABLE 37	NORTH AMERICA: PRECISION MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)	86
TABLE 38	EUROPE: PRECISION MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)	87
TABLE 39	ASIA PACIFIC: PRECISION MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)	87
7.3	RARE DISEASES	88
7.3.1	GROWING FOCUS ON PRODUCT DEVELOPMENT TO DRIVE MARKET	88
TABLE 40	PRECISION MEDICINE MARKET FOR RARE DISEASES, BY REGION, 2021-2028 (USD MILLION)	88
TABLE 41	NORTH AMERICA: PRECISION MEDICINE MARKET FOR RARE DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)	89

TABLE 42	EUROPE: PRECISION MEDICINE MARKET FOR RARE DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)	89
TABLE 43	ASIA PACIFIC: PRECISION MEDICINE MARKET FOR RARE DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)	89
7.4	INFECTIOUS DISEASES	90
7.4.1	RIISING INCIDENCE OF HIV AND TB TO FUEL MARKET	90
TABLE 44	PRECISION MEDICINE MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021-2028 (USD MILLION)	90
TABLE 45	NORTH AMERICA: PRECISION MEDICINE MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)	90
TABLE 46	EUROPE: PRECISION MEDICINE MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)	91
TABLE 47	ASIA PACIFIC: PRECISION MEDICINE MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)	91
7.5	HEMATOLOGICAL DISORDERS	91
7.5.1	INCREASING CASES OF SICKLE CELL DISEASE AND ANEMIA TO SUPPORT MARKET GROWTH	91
TABLE 48	PRECISION MEDICINE MARKET FOR HEMATOLOGICAL DISORDERS, BY REGION, 2021-2028 (USD MILLION)	92
TABLE 49	NORTH AMERICA: PRECISION MEDICINE MARKET FOR HEMATOLOGICAL DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)	92
TABLE 50	EUROPE: PRECISION MEDICINE MARKET FOR HEMATOLOGICAL DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)	93
TABLE 51	ASIA PACIFIC: PRECISION MEDICINE MARKET FOR HEMATOLOGICAL DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)	93
7.6	OTHER INDICATIONS	93
TABLE 52	PRECISION MEDICINE MARKET FOR OTHER INDICATIONS, BY REGION, 2021-2028 (USD MILLION)	94
TABLE 53	NORTH AMERICA: PRECISION MEDICINE MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)	94
TABLE 54	EUROPE: PRECISION MEDICINE MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)	95
TABLE 55	ASIA PACIFIC: PRECISION MEDICINE MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)	95
8	PRECISION MEDICINE MARKET, BY END USER	96
8.1	INTRODUCTION	97
TABLE 56	PRECISION MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION)	97
8.2	HOSPITALS AND CLINICS	97
8.2.1	WIDE ADOPTION OF PRECISION MEDICINE FOR COMPLEX MEDICAL PROCEDURES TO DRIVE MARKET	97
TABLE 57	PRECISION MEDICINE MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2021-2028 (USD MILLION)	98
TABLE 58	NORTH AMERICA: PRECISION MEDICINE MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021-2028 (USD MILLION)	98
TABLE 59	EUROPE: PRECISION MEDICINE MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021-2028 (USD MILLION)	99
TABLE 60	ASIA PACIFIC: PRECISION MEDICINE MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021-2028 (USD MILLION)	99
8.3	HOME CARE SETTINGS	100
8.3.1	ADVANTAGES OF PATIENT COMFORT AND REDUCED HOSPITAL STAYS TO SUPPORT MARKET GROWTH	100
TABLE 61	PRECISION MEDICINE MARKET FOR HOME CARE SETTINGS, BY REGION, 2021-2028 (USD MILLION)	100
TABLE 62	NORTH AMERICA: PRECISION MEDICINE MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021-2028 (USD MILLION)	100
TABLE 63	EUROPE: PRECISION MEDICINE MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021-2028 (USD MILLION)	101
TABLE 64	ASIA PACIFIC: PRECISION MEDICINE MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021-2028 (USD MILLION)	101
9	PRECISION MEDICINE MARKET, BY REGION	102
9.1	INTRODUCTION	103
TABLE 65	PRECISION MEDICINE MARKET, BY REGION, 2021-2028 (USD MILLION)	103
9.2	NORTH AMERICA	103
FIGURE 26	NORTH AMERICA: PRECISION MEDICINE MARKET SNAPSHOT	104
TABLE 66	NORTH AMERICA: PRECISION MEDICINE MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	104
TABLE 67	NORTH AMERICA: PRECISION MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)	105
TABLE 68	NORTH AMERICA: PRECISION MEDICINE MARKET, BY INDICATION, 2021-2028 (USD MILLION)	105

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 69 NORTH AMERICA: PRECISION MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION) 106

9.2.1 US 106

9.2.1.1 Rising regulatory approvals for therapeutic products to drive market 106

TABLE 70 PERSONALIZED MEDICINE PRODUCT APPROVALS BY US FDA 106

TABLE 71 US: PRECISION MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 107

TABLE 72 US: PRECISION MEDICINE MARKET, BY INDICATION, 2021-2028 (USD MILLION) 107

TABLE 73 US: PRECISION MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION) 108

9.2.2 CANADA 108

9.2.2.1 Rising incidence of cancer to drive market 108

TABLE 74 CANADA: PRECISION MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 108

TABLE 75 CANADA: PRECISION MEDICINE MARKET, BY INDICATION, 2021-2028 (USD MILLION) 109

TABLE 76 CANADA: PRECISION MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION) 109

9.2.3 NORTH AMERICA: RECESSION IMPACT 109

9.3 EUROPE 110

FIGURE 27 EUROPE: PRECISION MEDICINE MARKET SNAPSHOT 111

TABLE 77 EUROPE: PRECISION MEDICINE MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 112

TABLE 78 EUROPE: PRECISION MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 112

TABLE 79 EUROPE: PRECISION MEDICINE MARKET, BY INDICATION, 2021-2028 (USD MILLION) 113

TABLE 80 EUROPE: PRECISION MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION) 113

9.3.1 GERMANY 113

9.3.1.1 Rising R&D initiatives for therapeutics to drive market 113

TABLE 81 GERMANY: PRECISION MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 114

?

TABLE 82 GERMANY: PRECISION MEDICINE MARKET, BY INDICATION, 2021-2028 (USD MILLION) 114

TABLE 83 GERMANY: PRECISION MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION) 115

9.3.2 UK 115

9.3.2.1 Rising incidence of hematologic cancers to drive market 115

TABLE 84 UK: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040 115

TABLE 85 UK: PRECISION MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 116

TABLE 86 UK: PRECISION MEDICINE MARKET, BY INDICATION, 2021-2028 (USD MILLION) 116

TABLE 87 UK: PRECISION MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION) 117

9.3.3 FRANCE 117

9.3.3.1 Increasing initiatives in genomic research to drive market 117

TABLE 88 FRANCE: PRECISION MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 117

TABLE 89 FRANCE: PRECISION MEDICINE MARKET, BY INDICATION, 2021-2028 (USD MILLION) 118

TABLE 90 FRANCE: PRECISION MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION) 118

9.3.4 ITALY 118

9.3.4.1 Growing awareness initiatives for personalized treatment to propel market 118

TABLE 91 ITALY: PRECISION MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 119

TABLE 92 ITALY: PRECISION MEDICINE MARKET, BY INDICATION, 2021-2028 (USD MILLION) 119

TABLE 93 ITALY: PRECISION MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION) 120

9.3.5 SPAIN 120

9.3.5.1 Rising funding initiatives for cell and gene therapies to support market growth 120

TABLE 94 SPAIN: PRECISION MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 120

TABLE 95 SPAIN: PRECISION MEDICINE MARKET, BY INDICATION, 2021-2028 (USD MILLION) 121

TABLE 96 SPAIN: PRECISION MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION) 121

9.3.6 REST OF EUROPE 121

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 97	REST OF EUROPE: PRECISION MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)	122
TABLE 98	REST OF EUROPE: PRECISION MEDICINE MARKET, BY INDICATION, 2021-2028 (USD MILLION)	122
TABLE 99	REST OF EUROPE: PRECISION MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION)	123
9.3.7	EUROPE: RECESSION IMPACT	123
9.4	ASIA PACIFIC	123
TABLE 100	ASIA PACIFIC: PRECISION MEDICINE MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	124
TABLE 101	ASIA PACIFIC: PRECISION MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)	124
TABLE 102	ASIA PACIFIC: PRECISION MEDICINE MARKET, BY INDICATION, 2021-2028 (USD MILLION)	125
TABLE 103	ASIA PACIFIC: PRECISION MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION)	125
9.4.1	CHINA	125
9.4.1.1	High incidence of chronic diseases and large patient volume to fuel market	125
TABLE 104	CHINA: PRECISION MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)	126
TABLE 105	CHINA: PRECISION MEDICINE MARKET, BY INDICATION, 2021-2028 (USD MILLION)	126
TABLE 106	CHINA: PRECISION MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION)	127
9.4.2	JAPAN	127
9.4.2.1	Availability of reimbursements for medical procedures to support market growth	127
TABLE 107	JAPAN: PRECISION MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)	128
TABLE 108	JAPAN: PRECISION MEDICINE MARKET, BY INDICATION, 2021-2028 (USD MILLION)	128
TABLE 109	JAPAN: PRECISION MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION)	129
9.4.3	INDIA	129
9.4.3.1	Rising burden of chronic diseases to drive market	129
TABLE 110	INDIA: PRECISION MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)	130
TABLE 111	INDIA: PRECISION MEDICINE MARKET, BY INDICATION, 2021-2028 (USD MILLION)	130
TABLE 112	INDIA: PRECISION MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION)	131
9.4.4	AUSTRALIA	131
9.4.4.1	Rising R&D projects for genomic sequencing to propel market	131
TABLE 113	AUSTRALIA: PRECISION MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)	131
TABLE 114	AUSTRALIA: PRECISION MEDICINE MARKET, BY INDICATION, 2021-2028 (USD MILLION)	132
TABLE 115	AUSTRALIA: PRECISION MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION)	132
9.4.5	REST OF ASIA PACIFIC	132
TABLE 116	REST OF ASIA PACIFIC: PRECISION MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)	133
TABLE 117	REST OF ASIA PACIFIC: PRECISION MEDICINE MARKET, BY INDICATION, 2021-2028 (USD MILLION)	133
TABLE 118	REST OF ASIA PACIFIC: PRECISION MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION)	134
9.4.6	ASIA PACIFIC: RECESSION IMPACT	134
9.5	LATIN AMERICA	134
9.5.1	INVESTMENTS IN PRECISION MEDICINE DIAGNOSTICS TO SUPPORT MARKET GROWTH	134
TABLE 119	LATIN AMERICA: PRECISION MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)	135
TABLE 120	LATIN AMERICA: PRECISION MEDICINE MARKET, BY INDICATION, 2021-2028 (USD MILLION)	135
TABLE 121	LATIN AMERICA: PRECISION MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION)	136
9.5.2	LATIN AMERICA: RECESSION IMPACT	136
9.6	MIDDLE EAST	136
9.6.1	RIISING AWARENESS OF INNOVATIVE DIAGNOSTICS TO SUPPORT MARKET GROWTH	136
TABLE 122	MIDDLE EAST: PRECISION MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)	137
TABLE 123	MIDDLE EAST: PRECISION MEDICINE MARKET, BY INDICATION, 2021-2028 (USD MILLION)	137
TABLE 124	MIDDLE EAST: PRECISION MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION)	138

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

9.7	AFRICA	138
9.7.1	INCREASING COLLABORATIVE EFFORTS WITH ESTABLISHED COUNTRIES FOR PRECISION DIAGNOSTICS TO SUPPORT MARKET GROWTH	138
	TABLE 125	AFRICA: PRECISION MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
	TABLE 126	AFRICA: PRECISION MEDICINE MARKET, BY INDICATION, 2021-2028 (USD MILLION)
	TABLE 127	AFRICA: PRECISION MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION)
9.8	MIDDLE EAST & AFRICA: RECESSION IMPACT	139
10	COMPETITIVE LANDSCAPE	140
10.1	OVERVIEW	140
10.1.1	STRATEGIES ADOPTED BY KEY PLAYERS	141
10.2	MARKET SHARE ANALYSIS	142
	FIGURE 28	PRECISION MEDICINE MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2022)
	TABLE 128	PRECISION MEDICINE MARKET: INTENSITY OF COMPETITIVE RIVALRY
10.3	REVENUE SHARE ANALYSIS	143
	FIGURE 29	REVENUE SHARE ANALYSIS FOR KEY PLAYERS (2020?2022)
10.4	COMPANY EVALUATION MATRIX	144
	FIGURE 30	PRECISION MEDICINE MARKET: COMPANY EVALUATION MATRIX (2022)
10.4.1	STARS	145
10.4.2	PERVASIVE PLAYERS	145
10.4.3	EMERGING LEADERS	145
10.4.4	PARTICIPANTS	145
10.5	COMPANY EVALUATION MATRIX FOR STARTUPS/SMES	146
	FIGURE 31	COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022)
10.5.1	PROGRESSIVE COMPANIES	147
10.5.2	STARTING BLOCKS	147
10.5.3	DYNAMIC COMPANIES	147
10.5.4	RESPONSIVE COMPANIES	147
10.6	COMPETITIVE BENCHMARKING OF LEADING PLAYERS	147
10.6.1	PRODUCT FOOTPRINT OF COMPANIES	147
	TABLE 129	PRECISION MEDICINE MARKET: PRODUCT FOOTPRINT ANALYSIS
10.6.2	REGIONAL FOOTPRINT OF COMPANIES	149
	TABLE 130	PRECISION MEDICINE MARKET: REGIONAL FOOTPRINT ANALYSIS
10.7	COMPETITIVE BENCHMARKING OF STARTUPS/SMES	150
	TABLE 131	PRECISION MEDICINE MARKET: DETAILED LIST OF KEY STARTUPS/SMES
	TABLE 132	PRECISION MEDICINE MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES
10.8	COMPETITIVE SCENARIO AND TRENDS	151
10.8.1	PRODUCT APPROVALS	151
	TABLE 133	PRECISION MEDICINE MARKET: PRODUCT APPROVALS (JANUARY 2020?JUNE 2023)
10.8.2	DEALS	152
	TABLE 134	PRECISION MEDICINE MARKET: DEALS (JANUARY 2020?JUNE 2023)
10.8.3	OTHER DEVELOPMENTS	153
	TABLE 135	PRECISION MEDICINE MARKET: OTHER DEVELOPMENTS (JANUARY 2020?JULY 2023)
11	COMPANY PROFILES	154
	(Business overview, Products offered, Recent Developments, MNM view)*	
11.1	KEY PLAYERS	154
11.1.1	F. HOFFMANN-LA ROCHE LTD.	154
	TABLE 136	F. HOFFMANN-LA ROCHE AG: COMPANY OVERVIEW

FIGURE 32	F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)	155
TABLE 137	F. HOFFMANN-LA ROCHE AG: PRODUCT APPROVALS	157
11.1.2	BRISTOL MYERS SQUIBB	159
TABLE 138	BRISTOL MYERS SQUIBB: COMPANY OVERVIEW	159
FIGURE 33	BRISTOL MYERS SQUIBB: COMPANY SNAPSHOT (2022)	160
TABLE 139	BRISTOL MYERS SQUIBB: DEALS	161
TABLE 140	BRISTOL MYERS SQUIBB: PRODUCT APPROVALS	161
11.1.3	NOVARTIS AG	164
TABLE 141	NOVARTIS AG: COMPANY OVERVIEW	164
FIGURE 34	NOVARTIS AG: COMPANY SNAPSHOT (2022)	165
TABLE 142	NOVARTIS AG: DEALS	168
TABLE 143	NOVARTIS AG: PRODUCT APPROVALS	169
11.1.4	GILEAD SCIENCES, INC.	171
TABLE 144	GILEAD SCIENCES, INC.: COMPANY OVERVIEW	171
FIGURE 35	GILEAD SCIENCES, INC.: COMPANY SNAPSHOT (2022)	172
TABLE 145	GILEAD SCIENCES, INC.: DEALS	173
TABLE 146	GILEAD SCIENCES, INC.: PRODUCT APPROVALS	174
11.1.5	ASTRAZENECA	175
TABLE 147	ASTRAZENECA: COMPANY OVERVIEW	175
FIGURE 36	ASTRAZENECA: COMPANY SNAPSHOT (2022)	175
TABLE 148	ASTRAZENECA: DEALS	176
TABLE 149	ASTRAZENECA: PRODUCT APPROVALS	177
11.1.6	ABBVIE INC.	178
TABLE 150	ABBVIE INC.: COMPANY OVERVIEW	178
FIGURE 37	ABBVIE INC.: COMPANY SNAPSHOT (2022)	179
TABLE 151	ABBVIE INC.: DEALS	180
11.1.7	ELI LILLY AND COMPANY	181
TABLE 152	ELI LILLY AND COMPANY: COMPANY OVERVIEW	181
FIGURE 38	ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2022)	182
TABLE 153	ELI LILLY AND COMPANY: DEALS	183
TABLE 154	ELI LILLY AND COMPANY: OTHER DEVELOPMENTS	183
11.1.8	SAREPTA THERAPEUTICS, INC.	185
TABLE 155	SAREPTA THERAPEUTICS, INC.: COMPANY OVERVIEW	185
FIGURE 39	SAREPTA THERAPEUTICS: COMPANY SNAPSHOT (2022)	185
TABLE 156	SAREPTA THERAPEUTICS, INC.: DEALS	186
TABLE 157	SAREPTA THERAPEUTICS, INC.: PRODUCT APPROVALS	186
TABLE 158	SAREPTA THERAPEUTICS, INC.: OTHER DEVELOPMENTS	187
11.1.9	PFIZER INC.	188
TABLE 159	PFIZER INC.: COMPANY OVERVIEW	188
FIGURE 40	PFIZER INC.: COMPANY SNAPSHOT (2022)	189
TABLE 160	PFIZER INC.: DEALS	190
TABLE 161	PFIZER INC.: PRODUCT APPROVALS	191
TABLE 162	PFIZER INC.: OTHER DEVELOPMENTS	191
11.1.10	GLAXOSMITHKLINE PLC	192
TABLE 163	GLAXOSMITHKLINE PLC: COMPANY OVERVIEW	192
FIGURE 41	GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2022)	193
TABLE 164	GLAXOSMITHKLINE PLC: DEALS	195

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 165	GLAXOSMITHKLINE PLC: PRODUCT APPROVALS	195
11.1.11	SANOFI	197
TABLE 166	SANOFI: COMPANY OVERVIEW	197
FIGURE 42	SANOFI: COMPANY SNAPSHOT (2022)	198
TABLE 167	SANOFI: DEALS	199
TABLE 168	SANOFI: PRODUCT APPROVALS	200
11.1.12	JOHNSON & JOHNSON	202
TABLE 169	JOHNSON & JOHNSON: COMPANY OVERVIEW	202
FIGURE 43	JOHNSON & JOHNSON: COMPANY SNAPSHOT (2022)	203
TABLE 170	JOHNSON & JOHNSON: PRODUCT APPROVALS	204
11.1.13	BLUEBIRD BIO, INC.	205
TABLE 171	BLUEBIRD BIO, INC.: COMPANY OVERVIEW	205
FIGURE 44	BLUEBIRD BIO, INC.: COMPANY SNAPSHOT (2022)	205
TABLE 172	BLUEBIRD BIO, INC.: PRODUCT LAUNCHES	206
TABLE 173	BLUEBIRD BIO, INC.: PRODUCT APPROVALS	206
11.1.14	MERCK KGAA	208
TABLE 174	MERCK KGAA: COMPANY OVERVIEW	208
FIGURE 45	MERCK KGAA: COMPANY SNAPSHOT (2022)	209
TABLE 175	MERCK KGAA: PRODUCT APPROVALS	210
11.1.15	AMGEN, INC.	211
TABLE 176	AMGEN, INC.: COMPANY OVERVIEW	211
FIGURE 46	AMGEN, INC.: COMPANY SNAPSHOT (2022)	212
TABLE 177	AMGEN, INC.: DEALS	213
TABLE 178	AMGEN, INC.: PRODUCT APPROVALS	213
11.1.16	TAKEDA PHARMACEUTICAL COMPANY LIMITED	214
TABLE 179	TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY OVERVIEW	214
FIGURE 47	TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2022)	215
TABLE 180	TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT APPROVALS	216
11.1.17	REGENERON PHARMACEUTICALS, INC.	217
TABLE 181	REGENERON PHARMACEUTICALS, INC.: COMPANY OVERVIEW	217
FIGURE 48	REGENERON PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2022)	217
TABLE 182	REGENERON PHARMACEUTICALS, INC.: DEALS	218
TABLE 183	REGENERON PHARMACEUTICALS, INC.: PRODUCT APPROVALS	218
11.1.18	IMMUNOCORE LTD.	219
TABLE 184	IMMUNOCORE LTD.: COMPANY OVERVIEW	219
FIGURE 49	IMMUNOCORE LTD.: COMPANY SNAPSHOT (2022)	220
TABLE 185	IMMUNOCORE LTD.: DEALS	221
TABLE 186	IMMUNOCORE LTD.: PRODUCT APPROVALS	221
11.1.19	BLUEPRINT MEDICINES CORPORATION	222
TABLE 187	BLUEPRINT MEDICINES CORPORATION: COMPANY OVERVIEW	222
FIGURE 50	BLUEPRINT MEDICINE: COMPANY SNAPSHOT (2022)	222
TABLE 188	BLUEPRINT MEDICINES CORPORATION: DEALS	223
TABLE 189	BLUEPRINT MEDICINES CORPORATION: PRODUCT APPROVALS	224
11.2	OTHER PLAYERS	225
11.2.1	VERTEX PHARMACEUTICALS INCORPORATED	225
11.2.2	MIRATI THERAPEUTICS, INC	226
11.2.3	ARGENX SE	226

11.2.4	HORIZON THERAPEUTICS PLC	227
11.2.5	BRIDGEBIO PHARMA, INC.	227
11.2.6	TREVENA, INC.	228
11.2.7	INCYTE CORPORATION	228
11.2.8	ALNYLAM PHARMACEUTICALS, INC.	229
11.2.9	RIGEL PHARMACEUTICALS, INC.	229
11.2.10	TAIHO PHARMACEUTICAL CO., LTD (PART OF OTSUKA HOLDINGS CO., LTD.)	230
11.2.11	AGIOS PHARMACEUTICALS, INC.	230
11.2.12	SEAGEN, INC.	231
11.2.13	RHYTHM PHARMACEUTICALS, INC.	231
11.2.14	MACROGENICS, INC.	232

*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.

12	APPENDIX	233
12.1	DISCUSSION GUIDE	233
12.2	KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL	237
12.3	CUSTOMIZATION OPTIONS	239
12.4	RELATED REPORTS	239
12.5	AUTHOR DETAILS	240

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Precision Medicine Market by Type (Inhibitors, Monoclonal Antibodies, Cell & Gene Therapy, Antivirals, Antiretroviral), Indication (Oncology, Rare diseases, Hematology, Infectious), End user (Hospitals & Clinics, Home care) & Region - Global Forecast to 2028

Market Report | 2023-09-06 | 234 pages | MarketsandMarkets

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code*

Country*

Date

Signature